Stephen H. Leppla
37Patents
5h-index
41Co-inventors
69Inventor score
Filing activity: Feb 12, 1993 → Jan 20, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5677274A | Anthrax toxin fusion proteins and related methods | Chemistry; Metallurgy | 49 | Expired |
| US6592872B1 | Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein | Emerging Cross-Sectional Technologies | 43 | Expired |
| US5591631A | Anthrax toxin fusion proteins, nucleic acid encoding same | Chemistry; Metallurgy | 37 | Expired |
| US7261900B2 | Recombinant modified Bacillus anthracis protective antigen for use in vaccines | Human Necessities | 9 | Expired |
| US6485925B1 | Anthrax lethal factor is a MAPK kinase protease | Physics | 8 | Expired |
| US7097965B2 | Targeting antigens to the MHC class I processing pathway with an anthrax toxin fusion protein | Emerging Cross-Sectional Technologies | 5 | Expired |
| US7947289B2 | Multimeric protein toxins to target cells having multiple identifying characteristics | Chemistry; Metallurgy | 3 | Active |
| US7803386B2 | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli | Human Necessities | 3 | Expired |
| US7468352B1 | Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors | Chemistry; Metallurgy | 2 | Expired |
| US8388933B2 | Multimeric protein toxins to target cells having multiple identifying characteristics | Chemistry; Metallurgy | 2 | Active |
| US6893835B2 | Anthrax lethal factor is a MAPK kinase protease | Physics | 2 | Expired |
| US6911203B2 | Anthrax lethal factor is a MAPK kinase protease | Physics | 2 | Expired |
| US8071100B2 | Monoclonal antibodies that neutralize anthrax toxins | Physics | 1 | Active |
| US8961975B2 | Monoclonal antibodies that neutralize anthrax toxins | Physics | 1 | Active |
| US8481048B2 | Methods for preparing immunogenic conjugates | Human Necessities | 1 | Active |
| US9580492B2 | Monoclonal antibodies that neutralize anthrax toxins | Physics | 1 | Active |
| US8394387B1 | Recombinant modified Bacillus anthracis protective antigen for use in vaccines | Human Necessities | 1 | Active |
| US8044189B2 | Bacillus anthracis protective antigen nucleic acid sequences | Human Necessities | 1 | Active |
| US7763451B2 | Methods for preparing Bacillus anthracis protective antigen for use in vaccines | Human Necessities | 1 | Active |
| US8574853B2 | Monoclonal antibodies that neutralize anthrax toxins | Physics | 1 | Active |
| US8703150B2 | Methods of using Bacillus anthracis protective antigen sequences for vaccination | Human Necessities | 1 | Active |
| US9555064B2 | Protease-deficient Bacillus anthracis | Emerging Cross-Sectional Technologies | 1 | Active |
| US9730993B2 | Engineered anthrax lethal toxin for targeted delivery | Chemistry; Metallurgy | 1 | Active |
| US10273548B2 | Protease-deficient bacillus anthracis | Emerging Cross-Sectional Technologies | 0 | Active |
| US7625736B2 | Methods for preparing immunogenic conjugates | Human Necessities | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.